Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 7/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036447 | 1.00 | TSPO (0.79) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3035730 | 1.00 | TSPO (0.79) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3046250 | 0.89 | TSPO (0.81) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3046732 | 0.89 | TSPO (0.81) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3035734 | 0.89 | TSPO (0.81) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| Pk-11195 SCHEMBL31060347 | 0.89 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL15118334 | 0.89 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL12790424 | 0.89 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL29357086 | 0.89 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 | |
| (R)Pk-11195 SCHEMBL29477174 | 0.89 | TSPO (1.00) | TSPOMEN1KMT2ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064662-A1 | KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110064662-A1 | KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20110064662-A1 | KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY | RIKEN (JP) | 2011-03-17 | — | — | US | disclosed |
| EP-2228363-A1 | KIT FOR USE IN PRODUCTION OF MOLECULAR PROBE FOR PET DRUG SCREENING | Riken (JP) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064662-A1 | KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY | KIT, TPX2, RUNX1 | TSPO 241/4885MEN1 313/4885KMT2A 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.